Eugen Ruckhaberle
Overview
Explore the profile of Eugen Ruckhaberle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huebner H, Wimberger P, Laakmann E, Ruckhaberle E, Ruebner M, Lehle S, et al.
Precis Clin Med
. 2025 Jan;
8(1):pbae034.
PMID: 39839709
Background: Circulating cell-free tumor DNA (ctDNA) provides a non-invasive approach for assessing somatic alterations. The German PRAEGNANT registry study aims to explore molecular biomarkers and investigate their integration into clinical...
2.
Pruss M, Neubacher M, Dietzel F, Krawczyk N, Cieslik J, Mohrmann S, et al.
Breast Care (Basel)
. 2024 Oct;
19(5):270-281.
PMID: 39439862
Background: The COVID-19 pandemic has transformed breast cancer care for patients and healthcare providers. Circumstances varied greatly by region and hospital, depending on COVID-19 prevalence, case mix, hospital type, and...
3.
Jannusch K, Umutlu L, Kirchner J, Bruckmann N, Morawitz J, Herrmann K, et al.
J Nucl Med
. 2024 Oct;
65(12):1855-1861.
PMID: 39389629
Our rationale was to investigate whether F-FDG PET/MRI in addition to (guideline-recommended) conventional staging leads to changes in therapeutic management in patients with newly diagnosed breast cancer and compare the...
4.
Ruckhaberle E, Schmidt M, Welt A, Harbeck N, Wockel A, Gluz O, et al.
Geburtshilfe Frauenheilkd
. 2024 Sep;
84(9):813-836.
PMID: 39229634
Endocrine-based combination therapy with an inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6 inhibitors) is currently the first-line therapy of choice for patients with hormone receptor-positive (HR+) and human...
5.
Voss F, Nienhaus F, Pietrucha S, Ruckhaberle E, Fehm T, Melz T, et al.
Cardiooncology
. 2024 Jul;
10(1):43.
PMID: 39014463
Aims: Cancer therapy-related cardiac dysfunction (CTRCD) is a dreaded complication of anthracycline therapy. CTRCD most frequently appears in patients with cardiovascular risk factors (CVR) or known cardiovascular disease. However, limited...
6.
Untch M, Ditsch N, Fasching P, Busch S, Ettl J, Haidinger R, et al.
Geburtshilfe Frauenheilkd
. 2024 May;
84(5):431-442.
PMID: 38817599
The rationale behind the "International Consensus Conference for Advanced Breast Cancer" (ABC) is to standardize the treatment of patients with advanced or metastatic breast cancer worldwide using an evidence-based approach....
7.
Ditsch N, Untch M, Fasching P, Busch S, Ettl J, Haidinger R, et al.
Breast Care (Basel)
. 2024 Apr;
19(2):116-128.
PMID: 38638343
Background: The "International Consensus Conference for Advanced Breast Cancer" was initiated more than 10 years ago. The rationale was to standardize treatment of advanced breast cancer (ABC) based on available...
8.
Jaeger B, Krawczyk N, Japp A, Honisch E, Kohrer K, Scheuring S, et al.
Geburtshilfe Frauenheilkd
. 2023 Sep;
83(9):1138-1147.
PMID: 37706056
Introduction: The purpose of this feasibility study was to select targeted therapies according to "ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)". Data interpretation was further supported by a...
9.
Morawitz J, Bruckmann N, Jannusch K, Dietzel F, Milosevic A, Bittner A, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509307
This study compares the diagnostic potential of conventional staging (computed tomography (CT), axillary sonography and bone scintigraphy), whole-body magnetic resonance imaging (MRI) and whole-body F-fluorodeoxyglucose positron emission tomography (F-FDG PET/)MRI...
10.
Krawczyk N, Ruckhaberle E, Lux M, Fehm T, Greiling M, Osygus M
Geburtshilfe Frauenheilkd
. 2023 Mar;
83(3):321-332.
PMID: 36908284
HER2 positivity is one of the most important predictive factors in the treatment of breast cancer patients. Thanks to new targeted anti-HER2 drugs, the prognosis for HER2-positive breast cancer patients...